Insulet (PODD) Stock Forecast & Price Target

Insulet has demonstrated remarkable growth, achieving record new customer starts in the fourth quarter of 2025, with both year-over-year and sequential acceleration in performance. The company's revenue reached $784 million, marking a significant increase of 31% year-over-year, driven by robust volume growth and productivity gains across its manufacturing facilities. Notably, Insulet continues to invest heavily in its manufacturing capabilities, with fourth-quarter capital expenditures rising to $135 million, signaling a strong commitment to future growth and expansion in both existing and new markets.

Insulet's stock faces a negative outlook primarily due to increased competition in the insulin pump market and a significant decline in drug delivery revenues, which have dropped approximately 50%. The sentiment surrounding the company's performance has been negatively influenced by peers trading well below historical levels, particularly in the context of accelerated adoption of GLP-1 therapies. Additionally, projections indicate only modest growth in the U.S. and international markets for the Omnipod system, compounded by risks related to pipeline product approval delays and slower market expansion.